Zhou X, Wang J, Zhang J, Copley-Merriman C, Torigoe Y, Reyes C, Seymour JF, Offner FC, Trneny M, Salles GA. Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma. Hematology. 2015 Apr;129(36). doi: 10.1179/1607845414Y.0000000179
Wong-Sefidan I, Byrtek M, Zhou X, Dawson K, Friedberg J, Flowers CR, Zelenetz A, Reid E. Non-clinical factors drive imaging patterns after induction therapy of follicular lymphoma (FL): report from the National LymphoCare Study (NLCS). Poster presented at the 2013 12th International Conference on Malignant Lymphoma; June 2013. Lugano, Switzerland. [abstract] Hematol Oncol. 2013 Jun 17; 31(S1):255.
Mauskopf J, Chirila C, Birt J, Boye KS, Bowman L. Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: have they impacted the National Health Service budget? Health Policy (New York). 2013 Apr 1;110(1):49-59.
Dickey H, Ikenwilo D, Norwood P, Watson V, Zangelidis A. Utilisation of eye-care services: the effect of Scotland's free eye examination policy. Health Policy (New York). 2012 Dec;108(2-3):286-93. doi: 10.1016/j.healthpol.2012.09.006
Watson V, Sussex J, Ryan M, Tetteh E. Managing poorly performing clinicians: health care providers' willingness to pay for independent help. Health Policy (New York). 2012 Mar;104(3):260-71. doi: 10.1016/j.healthpol.2011.12.006
Richter A, Hicks KA, Earnshaw SR, Honeycutt AA. Allocating HIV prevention resources: a tool for state and local decision making. Health Policy (New York). 2008 Sep 1;87(3):342-9.
Lovas K, Kalo Z, McKenna SP, Whalley D, Pentek M, Genti G. Establishing a standard for patient-completed instrument adaptations in Eastern Europe: experience with the Nottingham Health Profile in Hungary. Health Policy (New York). 2003 Jan 1;63(1):20.
McKenna SP, Whalley D. Assessment of biotechnology drugs: what are the issues? Letter to the editor. Health Policy (New York). 1999 Nov;49(3):195-7. doi: 10.1016/S0168-8510(99)00055-X